Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.

ABSTRACT:

Background

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related death in the world with a five-year survival rate of less than 5%. Not all PDAC are the same, because there exist intra-tumoral heterogeneity between PDAC, which poses a great challenge to personalized treatments for PDAC.

Methods

To dissect the molecular heterogeneity of PDAC, we performed a retrospective meta-analysis on whole transcriptome data from more than 1200 PDAC patients. Subtypes were identified based on non-negative matrix factorization (NMF) biclustering method. We used the gene set enrichment analysis (GSEA) and survival analysis to conduct the molecular and clinical characterization of the identified subtypes, respectively.

Results

Six molecular and clinical

SUBMITTER: Zhao L 

PROVIDER: S-EPMC5975421 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature